TILs are also believed to be useful markers for predicting response to treatment in the TNBC and human epidermal growth factor receptor-2 (HER2)-positive breast cancer (HER2BC) subtypes, which are associated with high levels of immune activity [20]. Here, ERBB2 is linked to breast cancer.